Zanubrutinib in Combination With R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma
Active, not recruiting · Phase 1 · NCT04850495
Conditions: Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma
At a glance
- Research payments reported, 2025
- $80,254
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 38
About the trial
- Sponsor
- Yazeed Sawalha
- Tested
- Cyclophosphamide (drug), Doxorubicin Hydrochloride (drug), Prednisone (drug), Rituximab (biological), Vincristine Sulfate (drug), Zanubrutinib (drug)
- Dates
- Started 2021-11-16; completion 2026-12-15
- Results posted
- Not yet
This phase Ib trial seeks to find out the best dose and possible side effects and/or benefits of zanubrutinib in combination with the R-PolaCHP in treating patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). Zanubrutinib is designed to block a protein called Bruton Tyrosine Kinase in order to stop cancer growth. R-CHOP is the acronym for the combination of five drugs: rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone. It is the most widely used chemoimmunotherapy regimen for DLBCL and is considered the standard-of-care treatment for patients with DLBCL. Three of the drugs in R-CHOP (cyclophosphamide, doxorubicin and vincristine) are chemotherapy drugs. …
From ClinicalTrials.gov, last updated 2026-07-02. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Beigene, Ltd. reported $80,254 in research payments for this study in 2025 (1 payments).
Products named: Brukinsa
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- The Ohio State University Dba: Comprehensive Canc $80,254
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.